A Randomized, Investigator-masked Comparison of Diurnal Responder Rates with Bimatoprost and Latanoprost in the Lowering of Intraocular Pressure

Survey of Ophthalmology

Volumn 49, Issue 2 SUPPL. 1, 2004, Pages

  Choplin, Neil ^a   Bernstein, Paula ^b   Batoosingh, Amy L ^b   Whitcup, Scott M ^b  

^a San Diego   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Bimatoprost; Comparative study; Diurnal; Intraocular pressure; Latanoprost; Prospective studies; Responder rates

Indexed keywords

BIMATOPROST; LATANOPROST;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC;

EID: 1542268217     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2003.12.016     Document Type: Article

References (24)

1. The advanced glaucoma intervention study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 130:2000;429-440.
2. Alm A., Widengard I., Kjellgren D., et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 79:1995;12-16.
3. Altman D.G., Bland J.M. Absence of evidence is not evidence of absence. BMJ. 311:1995;485.
4. Asrani S., Zeimer R., Wilensky J., et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 9:2000;134-142.
5. Aung T., Chew P.T., Yip C.C., et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 131:2001;636-642.
6. Bergea B., Bodin L., Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 106:1999;997-1004.
7. Camras C.B., Alm A., Watson P., Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 103:1996;1916-1924.
8. DuBiner H., Cooke D., Dirks M., et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 45:(Suppl 4):2001;S353-S360.
9. Gandolfi S., Simmons S.T., Sturm R., et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 18:2001;110-121.
10. Gandolfi S.A., Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 110:2003;609-614.
11. Hedman K., Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 10:2000;95-104.
12. Hedman K., Larsson L.I. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 47:(Suppl 1):2002;S77-S89.
13. Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 120:2002;1268-1279.
14. Higginbotham E.J., Schuman J.S., Goldberg I., et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 120:2002;1286-1293.
15. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 120:2002;701-713.
16. Noecker R.S., Dirks M.S., Choplin N.T., et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 135:2003;55-63.
17. Nordmann J.P., Mertz B., Yannoulis N.C., et al. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am J Ophthalmol. 133:2002;1-10.
18. Oliver J.E., Hattenhauer M.G., Herman D., et al. Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision. Am J Ophthalmol. 133:2002;764-772.
19. Parrish R.K., Palmberg P., Sheu W.-P., XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 135:2003;688-703.
20. Preferred Practice Pattern: Primary Open-Angle Glaucoma. American Academy of Ophthalmology, 2000, pg 38
21. Quigley H.A., Enger C., Katz J., et al. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol. 112:1994;644-649.
22. Scherer W.J. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther. 18:2002;287-291.
23. Stewart W.C., Kolker A.E., Sharpe E.D., et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol. 130:2000;274-279.
24. Williams R.D. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther. 19:2002;275-281.